Psychiatric comorbidity in individuals at-risk for psychosis: Relationships with symptoms, cognition and psychosocial functioning.

AIM: Psychiatric comorbidity frequently occurs with at-risk mental state (ARMS) for psychosis. Its relationships with psychopathology, cognition and functioning, however, remain to be further clarified. We aimed to examine prevalence and correlates of psychiatric comorbidity, and its associations with psychosocial functioning and subjective quality-of-life (QoL) in a representative sample of Chinese ARMS individuals. METHODS: One hundred ten help-seeking participants aged 15 to 40 years with ARMS were recruited from a specialized early psychosis service in Hong Kong. ARMS status was verified by comprehensive assessment of at-risk mental state (CAARMS). Comorbid Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition non-psychotic psychiatric disorders at baseline were ascertained using diagnostic interview and medical record review. Assessments encompassing symptom profiles, psychosocial functioning, subjective QoL and a brief cognitive battery were conducted. RESULTS: Forty-nine (44.5%) ARMS participants were diagnosed as having comorbid non-psychotic psychiatric disorders at baseline, primarily depressive and anxiety disorders. Binary multiple logistic regression analysis revealed that female gender, more severe depressive symptoms, higher suicidality and poorer global cognitive functioning were independently associated with comorbid diagnosis status. ARMS participants with psychiatric comorbidity displayed significantly more limited extended social networks and poorer subjective QoL than those without psychiatric comorbidity. CONCLUSION: Comorbid disorders were frequently observed in Chinese ARMS individuals, and were linked to poorer cognition and higher suicide risk. Our findings underscore a potential critical role of psychiatric comorbidity in determining social functioning and subjective QoL in at-risk individuals. Further longitudinal research is required to clarify trajectories of comorbid disorder status and its prospective impact on clinical and functional outcomes in ARMS populations.

Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia.

BACKGROUND: The early course of first-episode mania with psychotic features (FEMP) is under-studied. Accumulating evidence suggests that FEMP is associated with substantial functional impairment. Very few studies were conducted to directly compare clinical and functional outcomes between FEMP and first-episode schizophrenia (FES). METHODS: Four-hundred-twenty patients aged 15-25 years who presented with FEMP or FES to a territory-wide early intervention service in Hong Kong from July 2001 to August 2003 and completed 3-year follow-up were studied. Baseline and follow-up variables were collected via systematic medial file review. Functional remission was operationalized as attaining sustained employment, and Social and Occupational Functioning Assessment Scale (SOFAS) score >60 in the last 12 months of follow-up. RESULTS: At baseline, FEMP patients were younger, more likely to be hospitalized, had shorter duration of untreated psychosis, more severe positive symptoms and lower SOFAS score than FES patients. By the end of 3-year follow-up, FEMP patients had significantly milder positive symptom severity, higher SOFAS score, and higher rates of sustained employment (45.7%) and functional remission (36.9%) than FES patients. Regression analyses showed that diagnostic group membership of FEMP (vs. FES) independently predicted better clinical and functional outcomes. CONCLUSION: Our results indicate that FEMP patients had better clinical and functional outcomes than FES patients in the initial 3 years of treatment. Yet, only approximately 37% of FEMP patients attained functional remission at 3 years. This underscores the need to develop specialized early intervention for FEMP populations to promote functional recovery in the early stage of illness.

Self-perceived cognitive functioning and its relationship with objective performance in first-episode schizophrenia: the Subjective Cognitive Impairment Scale.

BACKGROUND: Self-perceived cognitive dysfunction is under-recognized in clinical practice and under-studied in schizophrenia, particularly in the early illness stage. Findings on the relationship between subjective and objective cognitive measures were inconsistent. This study aimed to examine psychometric properties of a newly developed scale, Subjective Cognitive Impairment Scale (SCIS) and to investigate the relationship of self-reported ratings with objective test performance in first-episode schizophrenia. METHODS: One hundred one Chinese patients aged 18 to 64years presenting with first episode schizophrenia-spectrum disorder were studied. A comprehensive set of assessments examining objective cognitive functioning, clinical and treatment characteristic were administered. Internal consistency, factor structure and construct validity of SCIS were evaluated. Correlations of scale score with objective cognitive measures, clinical and treatment variables were examined. RESULTS: A single-factor underlying the structure of SCIS items was demonstrated by principal components analysis. Cronbach's alpha coefficient for the scale was 0.92. SCIS score was positively correlated with depression and anxiety symptom severity, and duration of untreated psychosis. SCIS score was not associated with other symptom dimensions, insight and chlorpromazine equivalents. No significant correlations were observed between SCIS score and objective cognitive measures with the exception of letter-number span test. CONCLUSION: Our results provided preliminary evidence in support of reliability and validity of SCIS in evaluating patient's cognitive complaints. A lack of correspondence between subjective and objective cognitive functioning suggested that they may represent two distinct constructs with potentially differential therapeutic implications. Further research is warranted to examine ecological validity and clinical utility of the scale.